-- 獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師的觀點摘要如下:Nokia2026年第一季業績符合預期,可比淨利為2.95億歐元(年成長93%),營業利潤為2.81億歐元(年成長54%),佔2026年預期值的17%。營收達45億歐元(以固定匯率計算年增4%),主要得益於人工智慧相關需求的成長,但電信業務疲軟和匯率波動抵消了部分成長。網路基礎設施業務推動成長,營收成長6%至18億歐元,其中光網路業務成長20%至8.21億歐元,主要得益於超大規模資料中心和人工智慧的需求;行動基礎設施業務溫和成長3%至25億歐元,營業利潤率提升380個基點至8.9%。管理層維持2026年全年可比營業利潤預期為20億至25億歐元,並將網路基礎設施成長預期從6%-8%上調至12%-14%,反映出人工智慧和雲端運算發展勢頭強勁。我們認為,人工智慧驅動的需求將繼續支撐這一前景,預計利潤率將逐步擴大,但業績仍與電信資本支出復甦和區域需求波動(尤其是在北美)密切相關。
Related Articles
National Australia Bank Shares Down After Resolution of Union Court Proceedings
National Australia Bank (ASX:NAB) shares were down about 1% in recent Monday trade following a Friday settlement with the Finance Sector Union of Australia to resolve court proceedings related to excessive additional working hours for employees.The settlement, reached on a without-admissions basis through mediation, includes the establishment of a health, safety, and well-being framework to mitigate the risks linked to working additional hours, and calls for greater oversight of such risks.The union and the bank said in a joint statement that they are "committed to continuing to work together to ensure fair and sustainable outcomes for all [National Australia Bank] employees."
Clinuvel Pharmaceuticals Says FDA Removes Post-Authorization Requirement for Implant
Clinuvel Pharmaceuticals (ASX:CUV) said the US Food and Drug Administration (FDA) removed a requirement for a post-authorization phase one study on cardiac repolarization in relation to its Scenesse implant upon reviewing its long-term safety profile, according to a Monday filing with the Australian bourse.Scenesse is used to treat patients with erythropoietic protoporphyria, a disease that causes intolerance to light.The FDA concluded that the study was no longer needed since it would not yield valuable safety information, the filing said.
XRF Scientific Completes Acquisition of Combustion Gas Analysis Business
XRF Scientific (ASX:XRF) has completed the acquisition of the combustion gas analysis business from Bruker AXS, according to a Monday Australian bourse filing.The company entered a binding agreement to acquire the combustion gas analysis business for $4 million upfront plus a potential $1 million earnout based on 7% of net revenue over three years, an earlier filing showed.